Saeki Hiroyuki, Sugimasa Yukio, Yamada Roppei, Akaike Makoto, Takemiya Shouji, Masaki Takahiro, Miyagawa Kaoru, Okawa Shinichi
Dept. of Digestive Surgery, Kanagawa Cancer Center.
Gan To Kagaku Ryoho. 2002 Nov;29(12):2221-3.
We evaluated the efficacy of IORT for unresectable Stage IVb (Japan Pancreas Society classification) pancreatic cancer. Twelve patients were treated with IORT, 17 with external beam radiotherapy (ERT) and 17 with chemotherapy (CHT, 8 patients doxorubicin-based, 7 patients 5-FU-based). Survival, hospital-free survival and pain relief were compared among the three groups. In the IORT group, 7 patients underwent bypass surgery, 3 celiac plexus blockade, 3 ERT, 2 hyperthermia and 2 CHT. In the ERT group, 1 patient underwent bypass surgery, 7 hyperthermia and 14 CHT. Distant metastases were more frequently found in the CHT group than in the IORT group. Median survival and median hospital-free survival were 208 and 79 days in the IORT group, 125 and 32 days in the ERT group and 76 and 9 days in the CHT group, respectively. Pain relief was obtained in 45% (5/11) of symptomatic patients after IORT and in 27% (4/15) after ERT. No patient (0/13) in the CHT group experienced pain relief. In conclusion, our experience suggests that IORT can reduce pain and improve QOL in patients with unresectable pancreatic cancer.
我们评估了术中放疗(IORT)用于无法切除的IVb期(日本胰腺学会分类)胰腺癌的疗效。12例患者接受了术中放疗,17例接受了外照射放疗(ERT),17例接受了化疗(CHT,8例基于阿霉素,7例基于5-氟尿嘧啶)。比较了三组患者的生存率、无住院生存率和疼痛缓解情况。在术中放疗组,7例患者接受了旁路手术,3例接受了腹腔神经丛阻滞,3例接受了外照射放疗,2例接受了热疗,2例接受了化疗。在外照射放疗组,1例患者接受了旁路手术,7例接受了热疗,14例接受了化疗。远处转移在化疗组比术中放疗组更常见。术中放疗组的中位生存期和中位无住院生存期分别为208天和79天,外照射放疗组为125天和32天,化疗组为76天和9天。术中放疗后45%(5/11)的有症状患者疼痛得到缓解;外照射放疗后,这一比例为27%(4/15)。化疗组没有患者(0/13)疼痛得到缓解。总之,我们的经验表明,术中放疗可减轻无法切除的胰腺癌患者疼痛并改善其生活质量。